Sunday 18 October 2026
Export PLRZ’s income statement to Excel — free account
Polyrizon Ltd.
PLRZ Healthcare Biotechnology
10.00
0.01
−0.10%
Follow PLRZ
| Older periods | Dec '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+3 more quarters Free account |
10.16 | 44.04 | 29.03 | 36.37 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | — | |
Capex/Depreciation |
0.00 | (0.01) | (0.02) | — | |
Intangible Assets out of Total Assets |
0.52 | 0.14 | 0.12 | 0.10 | |
Share Based Compensation of Revenue |
— | 0.00% | — | — | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | — | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(1.15) | (1.82) | (4.53) | — | |
Working Capital |
2.39 | 15.67 | 12.42 | 15.85 | |
Capital Expenditures |
0.00 | 0.00 | (0.01) | — | |
Net Current Asset Value |
2.39 | 15.67 | 12.42 | 15.85 | |
| Other line items | |||||
Quick Ratio |
9.79 | 43.48 | 28.14 | 35.88 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | — | |
Capex per Share |
0.00 | 0.00 | 0.00 | — | |
Average Assets |
— | 9.64 | 11.00 | 12.72 | |
Average Common Equity |
— | 8.74 | 10.40 | 12.19 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 30 Sep 2026